LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Biogen Inc

Biogen Inc

Suletud

Sektor Tervishoid

200.08 -0.66

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

199.46

Max

200.85

Põhinäitajad
By Trading Economics
Sissetulek	190M 584M
Müük	180M 2.5B
P/E Sektori keskmine	28.98 103.001
Aktsiakasum	5.28
Kasumimarginaal	23.628
Töötajad	7,570
EBITDA	237M 919M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+37 upside

Turustatistika
By TradingEconomics
Turukapital	122M 30B
Eelmine avamishind	200.74
Eelmine sulgemishind	200.08

Uudiste sentiment

By Acuity

34%

66%

64 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

198.19 / 204.86 Toetus ja vastupanu

Biogen Inc Graafik

Seotud uudised

6. sept 2024, 11:00 UTC

Peamised uudised

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29. mai 2024, 15:56 UTC

Tulu

Omandamised, ülevõtmised, äriostud

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4. okt 2023, 17:55 UTC

Omandamised, ülevõtmised, äriostud

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

37% tõus

12 kuu keskmine prognoos

Keskmine 275.11 USD 37%

Kõrge 342 USD

Madal 190 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Biogen Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

198.19 / 204.86Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

64 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.